Recursion Pharmaceuticals Inc (RXRX) — Strategic Asset Allocation Index
Recursion Pharmaceuticals Inc (RXRX) has a Strategic Asset Allocation Index of 19.1% as of June 2023. Strategic assets (PP&E of $89.77 Million plus long-term investments of $-) total $89.77 Million, measured against net assets of $468.96 Million. A higher index reflects capital-intensive or investment-heavy strategies where strategic assets dominate the equity base. Check asset resilience ratio of Recursion Pharmaceuticals Inc to evaluate the company's liquid asset resilience ratio.
SAAI
Strategic Assets
PP&E
Net Assets
Recursion Pharmaceuticals Inc Strategic Asset Allocation Index (2021–2022)
This chart shows how Recursion Pharmaceuticals Inc's Strategic Asset Allocation Index has evolved across 2 annual periods from 2021 to 2022. As of June 2023, the index stands at 19.1%, representing strategic assets of $89.77 Million against net assets of $468.96 Million USD. See RXRX financial flexibility index to measure the company's free cash flow as a share of total liabilities.
Annual Strategic Asset Allocation Index for Recursion Pharmaceuticals Inc (2021–2022)
The table below presents the year-by-year Strategic Asset Allocation Index for Recursion Pharmaceuticals Inc from 2021 to 2022, covering 2 annual filings. Each row shows PP&E, long-term investments, strategic assets combined, net assets, the index percentage, and the change in percentage points compared to the prior year. For the full company profile including market capitalisation, see RXRX market cap overview.
| Year | SAAI | Strategic Assets (USD) | PP&E | LT Investments | Net Assets | Change (pp) |
|---|---|---|---|---|---|---|
| 2022 | 25.0% | $121.45 Million | $121.45 Million | $- | $485.81 Million | ▲ +13.1 pp |
| 2021 | 11.9% | $64.72 Million | $64.72 Million | $- | $542.94 Million | — |